Lenalidomide Mylan Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

lenalidomide mylan

mylan ireland limited - lenalidomide - multiple myeloma - immunosuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Lenalidomide Krka d.d. Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

lenalidomide krka d.d.

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosuppressiva - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Zydelig Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Lenalidomide Accord Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

lenalidomide accord

accord healthcare s.l.u. - lenalidomide - multiple myeloma - immunosuppressiva - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide akkoord in combinatie met dexamethason is geïndiceerd voor de behandeling van multipel myeloom bij volwassen patiënten die minstens één eerdere therapie. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Imbruvica Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Bendamustine Accord 25 mg/ml inf. opl. (conc.) i.v. flac. Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bendamustine accord 25 mg/ml inf. opl. (conc.) i.v. flac.

accord healthcare b.v. - bendamustinehydrochloridemonohydraat 26,14 mg/ml - eq. bendamustinehydrochloride 25 mg/ml - concentraat voor oplossing voor infusie - 25 mg/ml - bendamustinehydrochloridemonohydraat 26.14 mg/ml - bendamustine

Tavneos Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

tavneos

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Lenalidomide Glenmark 10 mg, harde capsules Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

lenalidomide glenmark 10 mg, harde capsules

glenmark arzneimittel gmbh industriestrasse 31 82194 grobenzell (duitsland) - lenalidomide 10 mg/stuk - capsule, hard - ammonia (e 527) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; kaliumhydroxide (e 525) ; lactose 0-water ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zwarte inkt, ammonia (e 527) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; kaliumhydroxide (e 525) ; lactose 0-water ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zwarte inkt - lenalidomide

Lenalidomide Glenmark 15 mg, harde capsules Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

lenalidomide glenmark 15 mg, harde capsules

glenmark arzneimittel gmbh industriestrasse 31 82194 grobenzell (duitsland) - lenalidomide 15 mg/stuk - capsule, hard - ammonia (e 527) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; gelatine (e 441) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; kaliumhydroxide (e 525) ; lactose 0-water ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zwarte inkt, ammonia (e 527) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; gelatine (e 441) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; kaliumhydroxide (e 525) ; lactose 0-water ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zwarte inkt - lenalidomide

Lenalidomide Glenmark 2,5 mg, harde capsules Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

lenalidomide glenmark 2,5 mg, harde capsules

glenmark arzneimittel gmbh industriestrasse 31 82194 grobenzell (duitsland) - lenalidomide 2,5 mg/stuk - capsule, hard - ammonia (e 527) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; kaliumhydroxide (e 525) ; lactose 0-water ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zwarte inkt, ammonia (e 527) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; kaliumhydroxide (e 525) ; lactose 0-water ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zwarte inkt - lenalidomide